Josh Arnold Investment Consultant LLC Invests $736,000 in Neuronetics, Inc. $STIM

Key Points

• Josh Arnold Investment Consultant LLC acquired 200,000 shares of Neuronetics, Inc. for approximately $736,000, making it the 13th biggest holding in their portfolio.
• A total of 53.59% of Neuronetics stock is owned by hedge funds and institutional investors, reflecting growing interest in the company within the investment community.
• Neuronetics reported revenues of $38.11 million in its latest quarterly earnings, outperforming analysts' expectations, despite reporting a loss per share of ($0.15).

Josh Arnold Investment Consultant LLC acquired a new position in Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 200,000 shares of the company's stock, valued at approximately $736,000. Neuronetics accounts for approximately 0.6% of Josh Arnold Investment Consultant LLC's holdings, making the stock its 13th biggest holding. Josh Arnold Investment Consultant LLC owned about 0.30% of Neuronetics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Balyasny Asset Management L.P. raised its stake in Neuronetics by 29.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock valued at $2,386,000 after purchasing an additional 337,539 shares during the period. Ghisallo Capital Management LLC bought a new stake in Neuronetics during the 1st quarter valued at approximately $1,472,000. CenterBook Partners LP bought a new stake in Neuronetics during the 1st quarter valued at approximately $1,200,000. Cubist Systematic Strategies LLC bought a new stake in Neuronetics during the 1st quarter valued at approximately $1,055,000. Finally, AWM Investment Company Inc. bought a new stake in Neuronetics during the 1st quarter valued at approximately $905,000. Institutional investors own 53.59% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group decreased their target price on Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $7.00.

Neuronetics Price Performance

NASDAQ STIM traded down $0.08 during trading on Friday, hitting $3.23. 1,891,477 shares of the stock traded hands, compared to its average volume of 1,403,649. The company has a market capitalization of $213.57 million, a P/E ratio of -2.86 and a beta of 1.28. The firm has a 50-day simple moving average of $3.74 and a 200-day simple moving average of $3.98. The company has a quick ratio of 1.84, a current ratio of 2.02 and a debt-to-equity ratio of 1.76. Neuronetics, Inc. has a 12-month low of $0.52 and a 12-month high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The firm had revenue of $38.11 million for the quarter, compared to analysts' expectations of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Neuronetics, Inc. will post -1.13 EPS for the current year.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.